Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Nevada: - Carson Tahoe Regional Medical Center — Carson City, Nevada
- Cancer and Blood Specialists-Henderson — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada - Henderson — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada-Horizon Ridge — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada-Southeast Henderson — Henderson, Nevada
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Nevada: - Renown Regional Medical Center — Reno, Nevada
Phase 3 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positi…
Sponsor: Pfizer
NCT ID: NCT07062965
Sites in Nevada: - Comprehensive Cancer Centers of Nevada — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in th…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06966700
Sites in Nevada: - Optum Care Cancer Center ( Site 0050) — Las Vegas, Nevada
- Renown Regional Medical Center ( Site 0041) — Reno, Nevada
Phase 3 Recruiting Industry
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…
Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Sites in Nevada: - Comprehensive Cancer Centers of Nevada — Henderson, Nevada
Phase 3 Recruiting Industry
Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pemb…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06841354
Sites in Nevada: - Comprehensive Cancer Centers of Nevada ( Site 0015) — Las Vegas, Nevada
- Renown Regional Medical Center ( Site 0005) — Reno, Nevada
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Nevada: - OptumCare Cancer Care at Charleston — Las Vegas, Nevada
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation — Las Vegas, Nevada
- Summerlin Hospital Medical Center — Las Vegas, Nevada
- OptumCare Cancer Care at Fort Apache — Las Vegas, Nevada
- Renown Regional Medical Center — Reno, Nevada
Phase 2 Recruiting Industry
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in Nevada: - Cancer Care Specialists — Reno, Nevada
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Nevada: - Women's Cancer Center of Nevada — Las Vegas, Nevada
Phase 2 Recruiting Industry
A randomized study to determine safety and efficacy of a series of subcutaneous (SC) injections of HAL in patients with CINP, compared to matching placebo injections. After that, subjects may have the option to enter an Open Label extensio…
Sponsor: Dogwood Therapeutics Inc.
NCT ID: NCT06848348
Sites in Nevada: - Central Recruiting Site — Las Vegas, Nevada
Phase 1 Recruiting Industry
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.
Sponsor: Circle Pharma
NCT ID: NCT06577987
Sites in Nevada: - Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Nevada: - Carson Tahoe Regional Medical Center — Carson City, Nevada
- Cancer and Blood Specialists-Henderson — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada - Henderson — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada-Horizon Ridge — Henderson, Nevada
- Las Vegas Cancer Center-Henderson — Henderson, Nevada
NA Recruiting Network
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using marke…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03723928
Sites in Nevada: - Carson Tahoe Regional Medical Center — Carson City, Nevada
- Cancer and Blood Specialists-Henderson — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada - Henderson — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada-Horizon Ridge — Henderson, Nevada
- Las Vegas Cancer Center-Henderson — Henderson, Nevada
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Nevada: - OptumCare Cancer Care at Seven Hills — Henderson, Nevada
- OptumCare Cancer Care at Charleston — Las Vegas, Nevada